Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

57 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effectiveness, safety and quality of life of trifluridine/tipiracil in pretreated patients with metastatic colorectal cancer: Real-world data from the noninterventional TACTIC study in Germany.
Kröning H, Göhler T, Decker T, Grundeis M, Kojouharoff G, Lipke J, Semsek D, Moorahrend E, Sauer A, Bruch HR, Liersch R, Nusch A, Vehling-Kaiser U, Welslau M, Grunewald R, Harich HD, Stephany M, Uhlig J, de Buhr R, Frank M, Hogrefe C, Marschner N, Potthoff K, Hartmann F, Reisländer T, Schwaner I. Kröning H, et al. Among authors: potthoff k. Int J Cancer. 2023 Sep 15;153(6):1227-1240. doi: 10.1002/ijc.34603. Epub 2023 Jun 1. Int J Cancer. 2023. PMID: 37260368
Impact of performance status and transfusion dependency on outcome of patients with myelodysplastic syndrome, acute myeloid leukemia and chronic myelomonocytic leukemia treated with azacitidine (PIAZA study).
Wehmeyer J, Zaiss M, Losem C, Schmitz S, Niemeier B, Harde J, Hannig CV, Harich HD, Müller J, Klausmann M, Tessen HW, Potthoff K. Wehmeyer J, et al. Among authors: potthoff k. Eur J Haematol. 2018 Dec;101(6):766-773. doi: 10.1111/ejh.13160. Epub 2018 Oct 25. Eur J Haematol. 2018. PMID: 30091166
Final Effectiveness and Safety Results of NABUCCO: Real-World Data From a Noninterventional, Prospective, Multicenter Study in 697 Patients With Metastatic Breast Cancer Treated With nab-Paclitaxel.
Marschner N, Salat C, Söling U, Hansen R, Grebhardt S, Harde J, Nusch A, Potthoff K. Marschner N, et al. Among authors: potthoff k. Clin Breast Cancer. 2018 Dec;18(6):e1323-e1337. doi: 10.1016/j.clbc.2018.07.010. Epub 2018 Aug 10. Clin Breast Cancer. 2018. PMID: 30100104 Free article.
VicTORia: a randomised phase II study to compare vinorelbine in combination with the mTOR inhibitor everolimus versus vinorelbine monotherapy for second-line chemotherapy in advanced HER2-negative breast cancer.
Decker T, Marschner N, Muendlein A, Welt A, Hagen V, Rauh J, Schröder H, Jaehnig P, Potthoff K, Lerchenmüller C. Decker T, et al. Among authors: potthoff k. Breast Cancer Res Treat. 2019 Aug;176(3):637-647. doi: 10.1007/s10549-019-05280-2. Epub 2019 May 21. Breast Cancer Res Treat. 2019. PMID: 31115844 Clinical Trial.
Final results from IMPROVE: a randomized, controlled, open-label, two-arm, cross-over phase IV study to determine patients' preference for everolimus in combination with exemestane or capecitabine in combination with bevacizumab in advanced HR-positive, HER2-negative breast cancer.
Decker T, Söling U, Hahn A, Maintz C, Kurbacher CM, Vehling-Kaiser U, Sent D, Klare P, Hagen V, Chiabudini M, Falkenstein J, Indorf M, Runkel E, Potthoff K. Decker T, et al. Among authors: potthoff k. BMC Cancer. 2020 Apr 6;20(1):286. doi: 10.1186/s12885-020-06747-y. BMC Cancer. 2020. PMID: 32252684 Free PMC article. Clinical Trial.
Buparlisib in combination with tamoxifen in pretreated patients with hormone receptor-positive, HER2-negative advanced breast cancer molecularly stratified for PIK3CA mutations and loss of PTEN expression.
Welt A, Wiesweg M, Theurer S, Abenhardt W, Groschek M, Müller L, Schröder J, Tewes M, Chiabudini M, Potthoff K, Bankfalvi A, Marschner N, Schuler M, Breitenbücher F. Welt A, et al. Among authors: potthoff k. Cancer Med. 2020 Jul;9(13):4527-4539. doi: 10.1002/cam4.3092. Epub 2020 Apr 30. Cancer Med. 2020. PMID: 32352244 Free PMC article. Clinical Trial.
First-line pazopanib in intermediate- and poor-risk patients with metastatic renal cell carcinoma: Final results of the FLIPPER trial.
Staehler M, Panic A, Goebell PJ, Merling M, Potthoff K, Herrmann E, de Geeter P, Vannier C, Hogrefe C, Marschner N, Grünwald V. Staehler M, et al. Among authors: potthoff k. Int J Cancer. 2021 Feb 15;148(4):950-960. doi: 10.1002/ijc.33238. Epub 2020 Aug 18. Int J Cancer. 2021. PMID: 32738823 Free article. Clinical Trial.
Everolimus after failure of one prior VEGF-targeted therapy in metastatic renal cell carcinoma: Final results of the MARC-2 trial.
Staehler M, Stöckle M, Christoph DC, Stenzl A, Potthoff K, Grimm MO, Klein D, Harde J, Brüning F, Goebell PJ, Augustin M, Roos F, Benz-Rüd I, Marschner N, Grünwald V. Staehler M, et al. Among authors: potthoff k. Int J Cancer. 2021 Apr 1;148(7):1685-1694. doi: 10.1002/ijc.33349. Epub 2020 Oct 26. Int J Cancer. 2021. PMID: 33070307 Free article. Clinical Trial.
Patient, nurse, and physician preferences: final results of the CONVENIENCE study evaluating pegfilgrastim prophylaxis via pre-filled syringe or on-body injector in cancer patients.
Metz M, Semsek D, Rogmans G, Hutzschenreuter U, Fietz T, Harde J, Zacharias S, Hielscher C, Lorenz A, Zahn MO, Guth D, Liebers S, Berghorn M, Grebhardt S, Matillon CD, Egerer G, Potthoff K. Metz M, et al. Among authors: potthoff k. Support Care Cancer. 2021 Nov;29(11):6633-6643. doi: 10.1007/s00520-021-06230-9. Epub 2021 May 6. Support Care Cancer. 2021. PMID: 33956213 Free PMC article. Clinical Trial.
57 results